FULC - Fulcrum Therapeutics Inc Stock Price, Fair Value and News

$9.05+0.10 (+1.12%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

FULC Price Action

Last 7 days

-20.0%

Last 30 days

0.3%

Last 90 days

31.5%

Trailing 12 Months

140.1%

FULC RSI Chart

FULC Valuation

Market Cap

489.8M

Price/Earnings (Trailing)

-6.89

Price/Sales (Trailing)

6.24

Price/Free Cashflow

-8.11

FULC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FULC Fundamentals

FULC Revenue

FULC Earnings

Earnings (TTM)

-71.1M

Earnings Growth (Yr)

9.68%

Earnings Growth (Qtr)

-13.29%

FULC Profitability

Return on Equity

-35.85%

Return on Assets

-33.1%

Free Cashflow Yield

-12.34%

FULC Investor Care

Shares Dilution (1Y)

0.33%

Diluted EPS (TTM)

-1.13

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	0	41.3M	60.7M	80.0M
2023	4.0M	3.0M	2.6M	22.0M
2022	17.0M	14.5M	10.7M	6.3M
2021	12.9M	15.2M	18.3M	19.2M
2020	0	0	0	8.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Alexander C. Sapir
WEBSITE	fulcrumtx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	89

Fulcrum Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Fulcrum Therapeutics Inc? What does FULC stand for in stocks?

FULC is the stock ticker symbol of Fulcrum Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fulcrum Therapeutics Inc (FULC)?

As of Wed Dec 03 2025, market cap of Fulcrum Therapeutics Inc is 489.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FULC stock?

You can check FULC's fair value in chart for subscribers.

Is Fulcrum Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FULC is over valued or under valued. Whether Fulcrum Therapeutics Inc is cheap or expensive depends on the assumptions which impact Fulcrum Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FULC.

What is Fulcrum Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, FULC's PE ratio (Price to Earnings) is -6.89 and Price to Sales (PS) ratio is 6.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FULC PE ratio will change depending on the future growth rate expectations of investors.